Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Sonia JaramilloJohannes KrisamLucian Le CornetMarkus KratzmannLukas BaumannTim SauerMartina CrysandtAndreas RankDirk BehringerLino TeichmannMartin GörnerRalf-Ulrich TrappeChristoph RölligStefan KrauseMaher HanounOlaf HopferGerhard HeldSebastian BuskeLars FranseckySabine KayserChristoph SchliemannKerstin Schaefer-EckartYousef Al-FarehJörg SchubertThomas GeerMartin KaufmannArne BrechtDirk NiemannMeinhard KieserMartin BornhäuserUwe PlatzbeckerHubert ServeClaudia D BaldusCarsten Müller-TidowRichard F SchlenkPublished in: Trials (2021)
ClinicalTrials.gov NCT04093505 ; EudraCT 2019-003913-32. Registered on October 30, 2018.